Celltrion has shed further light on plans for its CT-P47 proposed biosimilar to Actemra/RoActemra (tocilizumab), revealing that it now has an approved global clinical trial design for the candidate as it prepares to push the product into Phase III.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?